Financial PerformanceSurvey results leave analysts confident in further revenue upside ahead for BSX, which is likely on track to sustain best-in-class revenue and EPS growth through 2028.
Market GrowthSurvey results suggest OPTION-driven indication expansion should lay the foundation for accelerating WATCHMAN growth, providing meaningful upside to out-year estimates.
Product AdoptionThe expert believes that the vast majority of the high risk afib ablation patients in the future will receive a Watchman, indicating a significant increase from the current adoption rate.